Given its stromal localization, targeting COL4A6 with antibody-drug conjugates (ADCs) or other therapeutic strategies may offer a novel approach to overcoming chemoresistance, as has been explored in pancreatic cancer [54]. Here, COL4A6 is linked to pancreatic neoplasm.